CURX.US Curanex Pharmaceuticals Inc Common Stock

Healthcare Biotechnology USA Stocks
4.80 USD
Close of Nov 14, 2026
3.58 13.33
Market cap
USD 7.53M
P/E
-
P/B
1.86x
ROE
-484.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CURX.US undervalued?

Graham number

The Graham number of Curanex Pharmaceuticals Inc Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Curanex Pharmaceuticals Inc Common Stock fundamental analysis

No fundamental analysis for Curanex Pharmaceuticals Inc Common Stock yet.

Curanex Pharmaceuticals Inc Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Curanex Pharmaceuticals Inc Common Stock

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharma…

Full company profile